Literature DB >> 32840732

Emodin Inhibits Lipopolysaccharide-Induced Inflammation by Activating Autophagy in RAW 264.7 Cells.

Yan-Jie Tu1,2, Bo Tan3, Lei Jiang1,2, Zhong-Hua Wu1,2, Hong-Ji Yu1,2, Xiao-Qian Li1,2, Ai-Dong Yang4,5.   

Abstract

OBJECTIVE: To investigate the effects of emodin on inflammation and autophagy in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages and reveal its underlying mechanism.
METHODS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was conducted to find the appropriate dose for emodin. RAW264.7 cells pretreated with different concentrations (0-50 μmol/L) of emodin or vehicle for 2 h prior to exposure to LPS for 16 h. Cell morphology was examined and propidium iodide staining was used to examine cell cycle. Expressions of inflammation-related proteins [nuclear factor-kappaB (NF-κ B) and I-kappaB (I κ B)α] and autophagy-related proteins [light chain (LC)3, P62/sequestosome 1, mammalian target of rapamycin (mTOR), and p-mTOR] were examined using Western blot analysis. Expression of inflammation-related cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 were detected by enzyme-linked immunosorbent assay. Autophagy was examined with LC3B fluorescence intensity and aggregation. The effect of emodin on autophagy was conducted with an autophagy inhibitor, 3-methyladenine (3-MA).
RESULTS: The expression of NF-κ B in LPS-induced cells was significantly increased (P<0.01) and simultaneously I κ B α decreased compared with the normal cell (P<0.05). The expressions of TNF-α, IL-β, and IL-6 proteins in the LPS-induced RAW264.7 cells were significantly higher than in the normal cell (P<0.05 or P<0.01). LPS increased the percentage of cells in the G0/G1 phase, which was recovered by emodin at different doses (12.5, 25, and 50μ mol/L, P<0.05 or P<0.01). The medium-dose (25 μ ml/L) emodin decreased the expressions of NF-κ B, P62 and p-mTOR (P<0.01) and increased I κ B α expression, LC3B II/I ratio as well as LC3B fluorescence intensity (P<0.05 or P<0.01). Meanwhile, the enhanced autophagic effects of emodin, such as the increment of LC3B II/ratio and the decrement of P62 expression, were suppressed by autophagy inhibitor 3-MA.
CONCLUSION: Emodin could inhibit inflammation of mice RAW264.7 macrophages induced by LPS, possibly through activating autophagy.

Entities:  

Keywords:  autophagy; emodin; inflammation; lipopolysaccharide

Year:  2020        PMID: 32840732     DOI: 10.1007/s11655-020-3477-9

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  1 in total

1.  Emodin ameliorates lipopolysaccharides-induced corneal inflammation in rats.

Authors:  Guo-Ling Chen; Jing-Jing Zhang; Xin Kao; Lu-Wan Wei; Zhi-Yu Liu
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

  1 in total
  4 in total

Review 1.  Effects of Anthraquinones on Immune Responses and Inflammatory Diseases.

Authors:  Dandan Xin; Huhu Li; Shiyue Zhou; Hao Zhong; Weiling Pu
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

2.  Emodin Promotes Autophagy and Prevents Apoptosis in Sepsis-Associated Encephalopathy through Activating BDNF/TrkB Signaling.

Authors:  Li-Li Gao; Zhi-Hao Wang; Yu-Hang Mu; Zuo-Long Liu; Li Pang
Journal:  Pathobiology       Date:  2021-12-06       Impact factor: 3.916

3.  Emodin relieves the inflammation and pyroptosis of lipopolysaccharide-treated 1321N1 cells by regulating methyltransferase-like 3 -mediated NLR family pyrin domain containing 3 expression.

Authors:  Bu Wang; Yuan Liu; Rui Jiang; Zhiliang Liu; Haiyun Gao; Fenqiao Chen; Jianqiang Mei
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  Anti-Inflammatory Effects and Mechanisms of Dandelion in RAW264.7 Macrophages and Zebrafish Larvae.

Authors:  Wenju Li; Fulong Luo; Xiaohui Wu; Bei Fan; Mingran Yang; Wu Zhong; Dongyan Guan; Fengzhong Wang; Qiong Wang
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.